Myelofibrosis is a heterogeneous disease and different hematologic manifestations, like anemia and thrombocytopenia, are variable based on the patients themselves. It might even be rare to see patients who experience myelofibrosis the same. So to take a deep dive into the treatment paradigm of this disease is Dr. Jennifer Caudle who will be speaking with Dr. Douglas Tremblay, Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.